The present invention provides a compound of the following formula, racemates, enantiomers and salts thereof. Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.
NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE
申请人:Calvet James P.
公开号:US20110082098A1
公开(公告)日:2011-04-07
Novobiocin analogues are useful in methods of treating, inhibiting, and/or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of mTOR pathway phosphoproteins P-mTOR, P-Akt and P-S6K, or combinations thereof. Further, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of Hsp-90 client proteins CFTR, ErbB2, c-Raf and Cdk4, or combinations thereof.
HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF
申请人:CHOY Allison Laura
公开号:US20100317624A1
公开(公告)日:2010-12-16
Compounds of formula (IA) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
The present invention provides a compound of the following formula and salts thereof:
Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.
Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors
作者:G.M. Kamal B. Gunaherath、Marilyn T. Marron、E.M. Kithsiri Wijeratne、Luke Whitesell、A.A. Leslie Gunatilaka
DOI:10.1016/j.bmc.2013.06.042
日期:2013.9
inhibitory activity, inhibits Heat shock protein 90 (HSP90) by binding weakly to a putative ATP-binding site within its C-terminus. To develop more potent HSP90 inhibitors that target this site and to define structure–activity relationships (SARs) for this class of compounds, we have synthesized twenty seven 3-amido-7-noviosylcoumarin analogues starting from NB and CA. These were evaluated for evidence of